Introduction
Fetal pleural effusion is an abnormality resulting from accumulation of fluid in the chest cavity, and the condition was first described by Carroll in 1977 (1) . Fetal pleural effusion is a rare condition, with a reported incidence ranging from 1/10,000 to 1/15,000 (2-4). The incidence of fetal pleural effusion in newborns ranges from 2.2 to 5.5 per 1,000 births (5) . The underlying causes of fetal pleural effusion are still unclear; it can occur as an initial symptom of hydrops fetalis, but it can also occur in isolation (6).
Causes and classifications
Fetal pleural effusion can be classified as primary fetal hydrothorax and secondary fetal hydrothorax. Primary fetal hydrothorax, also known as congenital chylothorax, can result from multiple lymphatic vessel anomalies or thoracic cavity defects caused by external force, a tumor, or cardiovascular diseases (7) . It can occur unilaterally or bilaterally and affects males more than females at a ratio of 2:1; primary fetal hydrothorax has a perinatal mortality rate of 22% to 53% (8, 9) . Secondary fetal hydrothorax is a feature of immune and nonimmune hydrops. Autoimmune conditions include Rh or ABO blood type incompatibility; non-immune factors include chromosomal abnormalities, genetic disorders, infections, congenital cardiac anomalies, congenital lung anomalies, hematologic diseases, metabolic diseases, and noncardiac anomalies (10) . Hydrops is usually bilateral, and is also often associated with ascites, pericardial effusion, subcutaneous edema, hydramnios, and placental thickening. The most common causes of non-immune hydrops are chromosomal anomalies such as Down syndrome and Turner syndrome, which can also be present with additional structural abnormalities (1,4).
Diagnosis
The treatment of fetal hydrothorax and patient prognosis are closely associated with its specific causes (11) (12) (13) (14) (15) ; therefore, a detailed prenatal examination and evaluation must be performed. Steps include identification of maternal blood type and screening serum specific antibodies to exclude immune hydrops, detection of infectious factors including TORCH, syphilis, and parvovirusB19, and performing a K-B test to exclude fetal maternal transfusion syndrome. A careful ultrasound examination should also be performed to observe the placenta, amniotic fluid, and fetal structure (and especially the fetal heart), and pulse Doppler should be used to detect the blood flow spectrum of the umbilical artery, middle cerebral artery, and venous system (16, 17) . Karyotyping or genetic testing is also routinely performed, especially in fetuses in which early pleural effusion has been detected (18-21).
Hydrothorax and chromosomal anomalies
Studies have shown that chromosomal anomalies are associated with fetal and/or neonatal hydrothorax. Table  1 summarizes the literature regarding characteristics and outcomes of Down syndrome cases involving patients with fetal or neonatal hydrothorax.
Treatment and prognosis
The prognosis for fetal pleural effusion is highly variable and difficult to predict, ranging from spontaneous resolution to progression to fetal hydrops and eventual perinatal death (59) (60) (61) (62) (63) (64) . The current strategy for treatment of fetal pleural effusion is based more on symptoms rather than underlying causes. Primary hydrothorax with small volumes of pleural fluid and no hydrops is more likely to resolve or remain stable, so more conservative treatment can be provided. Aubard et al. reported that the survival rate for conservative treatment of primary hydrothorax was 24% when hydrops was present and 75% when it was not (60), and Rustico et al. noted similar survival rates of 35% and 73%, respectively (4). Survival rates have improved significantly in recent years, and Wada et al. (21) reported survival rates of 58% and 97.8%, respectively, that can be largely attributed to improved methods of neonatal treatment. Thoracentesis is easy to perform and can reduce distress and improve fetal pulmonary development, but the procedure must be repeated after 24-48 hours in many patients, so thoracoamniotic shunting is usually recommended for fetuses with hydrops (65) . Recent studies have indicated that the survival rate for congenital hydrothorax with hydrops is around 60% for patients treated with thoracoamniotic shunting, approximately 50% for those treated with thoracentesis, and from 35% to about 60% for those receiving conservative treatment (4, 21) . 
